title: Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study.
abstract: BACKGROUND
  Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse.
  
  
  METHODS
  Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks in HIV-infected subjects on stable antiretroviral therapy, with a plasma HIV RNA <50 copies/mL, randomised to commence on a one to one basis darunavir/ritonavir (800/100 mg once daily) alone (DRVrMono) or with nucleoside analogues (DRVrNRTI). Patient-reported events were assessed by the Functional Assessment of HIV Infection (FAHI) questionnaire and included an assessment of cognitive function.
  
  
  RESULTS
  Of 256 subjects enrolled, clinician-reported grade 1-4 adverse events of the nervous system (all cause) were seen in 16% of patients in each treatment arm. FAHI questionnaires were completed by 206 subjects at 48 weeks. No differences in cognitive functioning or other FAHI scores were observed between study treatment groups: Cognitive Functioning score [mean (SD)] 8.9 (2.4) and 9.0 (2.6) in DRVrMono arm and 8.8 (2.6) and 8.9 (2.8) in DRVrNRTI arm at baseline and week 48, respectively (P value for difference = .76).
  
  
  CONCLUSIONS
  In this exploratory analysis, no differences in the evolution of neuropsychiatric adverse events over 48 weeks are observed in HIV-infected subjects randomised to switch antiretroviral therapy to darunavir/ritonavir with or without nucleoside reverse transcriptase inhibitors.
authors.affiliation: St. Mary's Hospital, Imperial College London, London, UK. a.winston@imperial.ac.uk
authors.forename: Alan
authors.initials: A
authors.lastname: Winston
authors.forename: Gerd
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: Jose
authors.initials: J
authors.lastname: Arribas
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Yvon
authors.initials: Y
authors.lastname: van Delft
authors.forename: Christiane
authors.initials: C
authors.lastname: Moecklinghoff
mesh_terms: D000328:Adult; D000368:Aged; D002493:Central Nervous System Diseases / Q000139:chemically induced / Q000453:epidemiology*; D000069454:Darunavir; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000453:epidemiology* / Q000209:etiology; D019438:Ritonavir / Q000009:adverse effects* / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir